Central serous chorioretinopathy: an update on pathogenesis and treatment (Q33712766)

28 July 2017

title

Central serous chorioretinopathy: an update on pathogenesis and treatment (English)

1 reference

28 July 2017

0 references

M. Gemenetzi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930852

29 July 2024

language of work or name

1 reference

8 October 2010

1 reference

full work available at URL

28 July 2017

https://www.nature.com/articles/eye2010130.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20930852

http://www.nature.com/articles/eye2010130.pdf

29 July 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

http://www.nature.com/articles/eye2010130

29 July 2024

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

29 July 2024

1 reference

28 July 2017

volume

24

1 reference

28 July 2017

issue

12

1 reference

28 July 2017

page(s)

1743-1756

1 reference

Type-A behavior and central serous chorioretinopathy.

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Peripheral Retinal Detachments and Retinal Pigment Epithelial Atrophic Tracts Secondary to Central Serous Pigment Epitheliopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

THE ETIOLOGICAL AGENT OF SEROUS CENTRAL CHORIORETINITIS

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

TRANSIENT MACULAR EDEMA DUE TO GRISEOFULVIN

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

The relationship of psychosocial factors to coronary heart disease in the Framingham study. I. Methods and risk factors

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

https://api.crossref.org/works/10.1038%2FEYE.2010.130

1 reference

7 January 2021

Central serous chorioretinopathy in a patient using methylenedioxymethamphetamine (MDMA) or "ecstasy".

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Experimental central serous chorioretinopathy in monkey eyes: fluorescein angiographic findings

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Digital indocyanine green videoangiography of central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Choroidal capillary and venous congestion in central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Central serous chorioretinopathy complicating systemic corticosteroid treatment

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Endogenous cortisol profile in patients with central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Central serous chorioretinopathy in endogenous hypercortisolism.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Psychosomatic interrelationships in ophthalmology

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Treatment of central serous choroidopathy with the beta receptor blocker metoprolol (preliminary results)

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

The long-term outcome of central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Retinal atrophy in idiopathic central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Photodynamic therapy in chronic central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Photodynamic therapy for chronic central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports).

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Indocyanine green angiography of central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Topical fundus pulsation measurement in patients with active central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Pathogenesis of central serous retinopathy: a new working hypothesis

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Experimental serous retinal detachment and focal pigment epithelial damage

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

New hypotheses on the pathogenesis and treatment of serous retinal detachment

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Idiopathic Serous Detachment of the Retinal Pigment Epithelium

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

The natural history of pigment epithelial detachment associated with central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Clinical characteristics of central serous chorioretinopathy in women

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Three-dimensional optical coherence tomographic findings of idiopathic multiple serous retinal pigment epithelial detachment.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Evaluation of central serous chorioretinopathy with optical coherence tomography

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Three-dimensional optical coherence tomographic findings in central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Alterations of retinal pigment epithelium in central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Morphological changes in the retinal pigment epithelium on spectral-domain OCT in the unaffected eyes with idiopathic central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Central serous chorioretinopathy: bilateral multifocal electroretinographic abnormalities

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Indocyanine green videoangiography of older patients with central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Involvement of corticosteroids and catecholamines in the pathogenesis of central serous chorioretinopathy: a rationale for new treatment strategies

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Corticosteroids and central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Central serous chorioretinopathy complicating solar retinopathy treated with glucocorticoids

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Posterior chorioretinopathy and retinal detachment after organ transplantation

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Six cases of central serous choroidopathy induced by systemic corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Visual loss from central serous retinopathy in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Systemic findings associated with central serous chorioretinopathy.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Central serous chorioretinopathy and glucocorticoids

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Sympathoadrenal system in stress. Interaction with the hypothalamic-pituitary-adrenocortical system

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Endocrine abnormalities in patients with central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Regulation of beta-adrenergic receptors by "permissive" hormones: glucocorticoids increase steady-state levels of receptor mRNA.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Non-genomic effects of glucocorticoids in the neural system. Evidence, mechanisms and implications

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Familial chronic central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Central serous chorioretinopathy after solid organ transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Cystoid macular degeneration in chronic central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Posterior cystoid retinal degeneration in central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Risk factors for posterior cystoid retinal degeneration in central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Retinal dysfunction in central serous retinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Isomerization and oxidation of vitamin a in cone-dominant retinas: a novel pathway for visual-pigment regeneration in daylight

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Experience With Nontreatment of Central Serous Choroidopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Long-term follow-up of idiopathic central serous chorioretinopathy without laser

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Five to 15 year follow-up of resolved idiopathic central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Contrast sensitivity after resolution of central serous retinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Bullous variant of idiopathic central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Bullous retinal detachment. An unusual manifestation of idiopathic central serous choroidopathy.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Subretinal Fibrosis in Central Serous Chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Cortisone in ocular disease: further studies

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Argon laser photocoagulation in the treatment of central serous retinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Long-term follow-up of central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Clinical characteristics of subretinal deposits in central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Argon laser photocoagulation treatment in central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Ocular changes after photodynamic therapy.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Low-fluence photodynamic therapy in longstanding chronic central serous chorioretinopathy with foveal and gravitational atrophy.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Prognostic factors related to photodynamic therapy for central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Subfoveal choroidal thickness after treatment of central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Indocyanine green enhanced subthreshold diode-laser micropulse photocoagulation treatment of chronic central serous chorioretinopathy.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Micropulse diode laser photocoagulation for central serous chorio-retinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

A new strategy of treatment with low-dosage acetyl salicylic acid in patients affected by central serous chorioretinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.130

7 January 2021

Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. Albrecht von Graefe's archive for clinical and experimental ophthalmology

1

12

211

A Von Graefe

1866

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

Transactions - American Academy of Ophthalmology and Otolaryngology

29 July 2024

7

69

605

AE Maumenee

1965

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

Klinische Monatsblaetter fuer Augenheilkunde

29 July 2024

15

97

345

S Kitahara

1936

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. Albrecht von Graefe's archive for clinical and experimental ophthalmology

29 July 2024

16

00

000

H Reiger

1960

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

Transactions - American Academy of Ophthalmology and Otolaryngology

29 July 2024

26

56

220

C Berens

1952

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

Nippon Ganka Gakkai zasshi

29 July 2024

28

75

1720

K Nagayoshi

1971

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

Nippon Ganka Gakkai zasshi

29 July 2024

29

76

1037

T Miki

1972

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

Nippon Ganka Gakkai zasshi

29 July 2024

41

95

1181

H Yoshioka

1991

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

Stereoscopic Atlas of Macular Diseases

29 July 2024

60

1

52

JD Gass

1997

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

Japanese journal of clinical ophthalmology

29 July 2024

88

46

729

H Matsunaga

1992

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

29 July 2024

https://api.crossref.org/works/10.1038/EYE.2010.130

104

24

927

PA Erickson

1983

1 reference

29 July 2024

https://api.crossref.org/works/10.1038/EYE.2010.130

105

27

168

DH Anderson

1986

1 reference

29 July 2024

https://api.crossref.org/works/10.1038/EYE.2010.130

107

31

1259

T Mori

1990

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

29 July 2024

Annals of ophthalmology

117

12

920

WE Benson

1980

1 reference

Transactions - American Academy of Ophthalmology and Otolaryngology

29 July 2024

119

55

565

JM McLean

1951

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

Klinische Monatsblaetter fuer Augenheilkunde

29 July 2024

123

131

536

A Bialasiewicz

1957

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

Transactions - American Academy of Ophthalmology and Otolaryngology

29 July 2024

126

78

205

RC Watzke

1974

1 reference

https://api.crossref.org/works/10.1038/EYE.2010.130

29 July 2024

https://api.crossref.org/works/10.1038/EYE.2010.130

134

40

2322

D Husain

1999

1 reference

29 July 2024

Identifiers

DOI

10.1038/EYE.2010.130

1 reference

Dimensions Publication ID

28 July 2017

1003930587

0 references

1 reference